- Details
- Description
-
Packaging Size60C/bottle
-
Strength100mg
-
CompositonAcalabrutinib
-
TreatmentChronic lymphocytic leukemia (CLL),small lymphocytic lymphoma (SLL),Mantle Cell Lymphoma（MCL）
-
FormCapsule
-
BrandAKADX
-
Quantity Unit100mg*60C/bottle
-
ManufacturerBIGBEAR Pharma,LAOs PDR
Acalabrutinib is used to treat people with mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other chemotherapy medication. It is also used alone or with obinutuzumab (Gazyva) to treat chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) and small lymphocytic lymphoma (SLL: a type of cancer that begins in the white blood cells). Acalabrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
ADULT
Mantle Cell Lymphoma
Indicated for mantle cell lymphoma (MCL) in patients who have received ≥1 prior therapy
100 mg PO q12hr
Continue until disease progression or unacceptable toxicity
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Indicated for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Monotherapy
- 100 mg PO q12hr
- Continue until disease progression or unacceptable toxicity
Combination with obinutuzumab
- Indicated for patients with previously untreated CLL or SLL
- Start acalabrutinib at Cycle 1 (each cycle is 28 days)
- Start obinutuzumab at Cycle 2 for a total of 6 cycles
- Refer to obinutuzumab for infusion rates
-
Cycle 1
- Days 1-28: Acalabrutinib 100 mg PO q12hr
-
Cycle 2
- Days 1-28: Acalabrutinib 100 mg PO q12hr
- Day 1: Obinutuzumab 100 mg IV infusion
- Day 2: Obinutuzumab 900 mg IV infusion
- Days 8 and 15: Obinutuzumab 1000 mg IV infusion
-
Cycles 3-7
- Day 1-28: Acalabrutinib 100 mg PO q12hr
- Day 1: Obinutuzumab 1000 mg IV infusion
-
Cycle 8 and subsequent cycles
- Day 1-28: Acalabrutinib 100 mg PO q12hr
- Continue until disease progression or unacceptable toxicity
